Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
G-NiiB GenieBiome is a biotechnology company specializing in microbiome-based solutions, founded as a spinout from The Chinese University of Hong Kong (CUHK). The company leverages a massive Asian-specific microbiome database and AI-driven metagenomics to develop precision diagnostics and therapeutic formulas. Its product portfolio includes the G-NiiB series of synbiotic supplements targeting immunity, gut health, skin conditions, and mental wellness, as well as the M3CRC non-invasive colorectal cancer risk test. With a focus on the Asian population, GenieBiome aims to transform microbiome science into evidence-based health solutions across diagnostics and live biotherapeutic products.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on G-NiiB GenieBiome.